Prodrugs for nasal drug delivery

Area of Science:

• Pharmacology
• Drug Delivery
• Biotechnology

Background:

• Nasal drug delivery is gaining traction due to its advantages like rapid onset and high systemic availability.
• The nasal epithelium facilitates transport of both charged and uncharged xenobiotics.
• Nasal mucosa contains metabolizing enzymes (e.g., aldehyde dehydrogenase, glutathione transferases, P450 monooxygenases) that can be leveraged for drug design.

Purpose of the Study:

• To review recent advances in peptide nasal delivery using prodrug modifications.
• To examine nasally delivered therapeutic agents for various disease states.
• To highlight the potential of prodrug design for improving nasal drug absorption and systemic availability.

Main Methods:

• Literature review of prodrug strategies for nasal peptide delivery.
• Analysis of therapeutic agents delivered via the nasal route.
• Discussion of the role of nasal mucosal enzymes in drug metabolism and prodrug design.

Main Results:

• Prodrug modification is a viable strategy to enhance peptide absorption and systemic availability via nasal delivery.
• Various therapeutic agents can be effectively delivered nasally for targeted disease treatment.
• Understanding nasal enzymatic activity aids in designing effective prodrugs for improved pharmacokinetic profiles.

Conclusions:

• Nasal drug delivery, particularly with prodrug strategies, presents a promising route for enhanced therapeutic agent administration.
• Prodrug design can overcome absorption limitations and improve systemic availability for peptide and other xenobiotics.
• Further research into prodrugs and nasal delivery systems can optimize treatment for diverse medical conditions.